Mobia Medical (NASDAQ:MOBI) Director Buys 35,572 Shares

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey acquired 35,572 shares of Mobia Medical stock in a transaction that occurred on Thursday, August 13th. The shares were purchased at an average cost of $11.51 per share, with a total value of $409,433.72. Following the completion of the acquisition, the director owned 268,904 shares of the company’s stock, valued at $3,095,085.04. The trade was a 15.25% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Mobia Medical Stock Performance

MOBI opened at $11.74 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.80 and a current ratio of 13.28. The stock has a market capitalization of $390.84 million and a P/E ratio of -0.61. Mobia Medical, Inc. has a one year low of $10.19 and a one year high of $15.29. The business’s fifty day moving average price is $12.42.

Mobia Medical (NASDAQ:MOBI) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The firm had revenue of $13.51 million during the quarter. Mobia Medical’s revenue was up 102.4% on a year-over-year basis. On average, analysts predict that Mobia Medical, Inc. will post -2.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MOBI. Weiss Ratings initiated coverage on shares of Mobia Medical in a report on Wednesday, August 12th. They set a “sell (e-)” rating for the company. Wolfe Research assumed coverage on shares of Mobia Medical in a research report on Tuesday, June 2nd. They issued an “outperform” rating on the stock. Wall Street Zen raised shares of Mobia Medical from a “sell” rating to a “hold” rating in a research note on Sunday, June 14th. BTIG Research restated a “buy” rating and set a $19.00 price objective on shares of Mobia Medical in a research report on Wednesday, August 12th. Finally, Bank of America started coverage on Mobia Medical in a research report on Tuesday, June 2nd. They set a “buy” rating and a $16.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.75.

About Mobia Medical

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.